ムラガキ　ヨシヒロ   MURAGAKI Yoshihiro   村垣　善浩    所属   医学部 医学科（東京女子医科大学病院）    職種   客員教授
論文種別	症例報告
言語種別	英語
査読の有無	査読あり
表題	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
掲載誌名	正式名：Journal of neuro-oncology 略　 称：J Neurooncol ISSNコード：0167594X/15737373
掲載区分	国外
巻・号・頁	144(1),pp.205-210
著者・共著者	LASSMAN Andrew B†., ALDAPE Kenneth D. , ANSELL Peter J. , BAIN Earle , CURRAN Walter J., EOIL Marica , FRENCH Pim J. , KINOSHITA Manabu , LOOMAN Jim , MRHTA Minesh, MURAGAKI Yoshihiro, NARITA Yoshitaka, OCAMPO Christopher , LISA Roberts-Rapp, SONG Minghao , VOGELBAUM Michael A., WALENKAMP Annemiek M. E., WANG Tony J. C. , ZHANG Peixin, van den BENT Martin J.
発行年月	2019/08
概要	Purpose Epidermal growth factor receptor (EGFR) amplification has been reported to occur in ~ 50% of glioblastomas (GBMs). We are conducting several global studies that require central testing for EGFR amplification during screening, representing an opportunity to confirm the frequency of amplification in GBM in a large cohort and to evaluate whether EGFR amplification differs by region of the world. Methods EGFR amplification was measured by fluorescence in situ hybridization during screening for therapeutic trials of an EGFR antibody–drug conjugate: two Phase 2/3 global trials (INTELLANCE-1, INTELLANCE-2), and a Japanese Phase 1/2 trial (INTELLANCE-J). We evaluated the proportion of tumor tissue samples harboring EGFR amplification among those tested and differences in amplification frequency by geography. Results EGFR was amplified in 54% of 3150 informative cases screened for INTELLANCE-1 and -2, consistent with historic controls, but was significantly lower in patients from Asia versus the rest of the world (35% vs. 56%, P < 0.0030). The independent INTELLANCE-J trial validated this finding (33% amplified of 153 informative cases). Conclusions EGFR amplification occurs less frequently in patients from Asia than elsewhere. Further study is required to understand biological differences to optimize treatment in glioblastoma.
DOI	10.1007/s11060-019-03222-y
PMID	31273577